Recombinant Hepatitis E Vaccine (Escherichia Coli)
Asset
Induces protective immunity against hepatitis E virus using recombinant viral antigen.
- Stage
- Phase 3
- Modality
- Vaccine
- Target
- Not known
- 6
- Indications
- 17
- Trials
- 1
- Developer
Indications
6Cervical cancer
Phase 3, Completed, NCT05426148, clinicaltrials.gov, 12 Oct 2026
Cervical intraepithelial neoplasia
Phase 3, Completed, NCT05426148, clinicaltrials.gov, 12 Oct 2026
Hepatitis e
Phase 3, Completed, NCT06564116, clinicaltrials.gov, 12 Oct 2026
3 more
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials17
- Evidence for its targets1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 12 Oct 2026, 3 sources